E-Folder - Business

Companies that close their books fast will experience the interrelated benefits of faster access to financial information, better-informed decision

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

making, more efficient processes, reduced man-hours, cost savings and a healthier image in the market. But as companies seek to achieve a fast clo

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

se, the poor performance of some consolidation applications is becoming an increasing significant barrier to their efforts.

“With our legacy in fi

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

ance we are keenly aware of the pressure companies are under to achieve a fast close and create sustainable compliance processes,” says Crispin Rea

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

d, chief marketing officer at Cartesis. “The benchmark results show how a powerful business performance management framework can support a high num

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

ber of users with the speed and accuracy financial executives demand. At the end of the day this level of performance translates hours into minutes

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

and has a tangible impact on close times.”

Fast Technology for a Fast Close

The tests, run on Microsoft SQL Server 2005 and HP Integri

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

ty hardware, demonstrate Cartesis Finance's ability to:

Support 1,500 active concurrent users while performing financial consolidation
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
li>
Support 12 simultaneous consolidations running with up to 500 active users in one application
Achieve average response times, on

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

100 user actions, of under three seconds

Scale the applications with new users while maintaining performance

The results als

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

o demonstrate the importance of a company scrutinizing its IT infrastructure to identify processes and technologies that impede a fast close as wel

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

l as the value of implementing high-performance applications and strategies to achieve one. The expanding scope and increasingly large deployments

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

f financial applications means what was once hundreds of users is now in the area of thousands. This makes it increasingly important for an IT infr

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

astructure to support mission-critical applications with high availability, high scalability and high reliability to provide users with the flawles

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

s performance they demand.

The testing was conducted by Cartesis in a Microsoft Technology Center on Microsoft SQL Server 2005 and HP server hardw

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

re and leveraged Compuware's QALoad solution to simulate, through real-life usage scenarios and user profiles, the equivalent of six months of actu

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

al reporting cycles involving more than 14,000 data submissions and 160,000 input schedules.

Get More on Getting Faster

During an online s

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

eminar on March 22, Cartesis will demonstrate the importance of high-performance applications, using real-world fast close success stories from lea

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

ing global companies like Roche, Nissan, Barry Callebaut, Recticel, Sartorius and Soci?t? G?n?rale, where close times have been reduced by as much

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

as 75 percent. The event, co-hosted by Microsoft and HP, will also showcase highlights of the benchmark results. By: James Fisher and Dean Lombard

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.e-folder.org.ua/article/44309/e-folder-Proven-Cartesis-Performance-Offers-Foundation-for-Customers-Fast-Close-Success.html">Proven Cartesis Performance Offers Foundation for Customers' Fast Close Success</a>

BB link (for phorums):
[url=http://www.e-folder.org.ua/article/44309/e-folder-Proven-Cartesis-Performance-Offers-Foundation-for-Customers-Fast-Close-Success.html]Proven Cartesis Performance Offers Foundation for Customers' Fast Close Success[/url]

Business in the UK’s freight shipping industry has been booming over recent months. The port of Belfast is experiencing one of the busiest periods in its 400 year history. And now figures from the country's leading sea freight lines show that freight shipping volumes increased by 8% between 2004 and 2005.

If you can identify who you are working with, it makes it easier to work with them.

If “resignation” is the word that strikes fear into all employers, then “counteroffer” is the one that strikes fear into an employee’s heart. Jeff Altman, CPC, MSW offers a search professional's view of how to and whether to consider a counteroffer.

Tags

Links

E-Folder - Proven Cartesis Performance Offers Foundation for Customers' Fast Close Success

Related Articles: